Gossamer Bio (GOSS) Q1 2026 earnings summary

Executive summary

• Focused on developing and commercializing seralutinib for pulmonary hypertension, with a key partnership under the Chiesi Collaboration Agreement for global development and commercialization activities.

• Reported positive topline results from the Phase 3 PROSERA Study in PAH, though the primary endpoint narrowly missed the prespecified alpha threshold.

• Plans to submit a New Drug Application for seralutinib in September 2026, pending regulatory feedback.

• Paused enrollment in the Phase 3 SERANATA Study for PH-ILD to evaluate resource allocation and implications of PROSERA results.

Financial highlights

• Revenue for Q1 2026 was $17.0 million, up from $9.9 million in Q1 2025, driven by increased research and development and pre-commercial services under the Chiesi agreement.

• Net loss for Q1 2026 was $46.7 million, compared to $36.6 million in Q1 2025, reflecting higher R&D and G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $99.2 million as of March 31, 2026.

• Accumulated deficit reached $1,485.6 million as of March 31, 2026.

Outlook and guidance

• Existing cash resources are expected to fund operations into Q1 2027.

• Ongoing need for additional capital to support continued development and potential commercialization of seralutinib.

• Plans to resume PH-ILD development work when feasible, based on resource allocation and regulatory feedback.